Clinical Trial Search

Primary: Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6 — -30.8; -10.9 Percent — p=<0.001

Primary: Sustained Virologic Response, Defined as a Plasma HCV-RNA (Hepatitis C Ribonucleic Acid) Level Below the LLQ (Lower Level of Quantitation) at 24 Weeks Post-treatment…

Primary: Number of Subjects Achieving ACR20 (at Least 20% Improvement in American College of Rheumatology Criteria From Baseline) at Week 16 — 44; 32 participants — p=0.0210

Primary: Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination — 717.5; 844.9 gpELISA units/mL

Primary: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 18 — -1.03; -0.31 Percent — p=<0.001

Primary: Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo). — 0; 19; 13 participants — p=0.0014

Primary: Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo). — 0; 18; 7 participants — p=<0.0001

Primary: Summary of Forteo B Pen Complaints at 8 Weeks — 47; 4; 27; 8 number of complaints

Primary: Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 — -4.3; -7.9; -8.6 mm Hg

Primary: Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 — -2.0; -5.8; -6.3; -8.0 mm Hg

Primary: Mean Changes From Baseline to 6 Week and 24 Week Endpoints in the Multidimensional Assessment of THYmic States Scale (MATHYS) Total Score — 140.55; 136.52; 116.74; 76.88…

Primary: Percentage of Participants With Corticosteriod-free Clinical Remission — 30.0; 44.4; 56.8 percentage of participants — p=<0.001

Primary: Gingivitis Index — 1.00; 1.27 Units on a scale — p=0.05

Primary: Change in Hemoglobin A1c Between 52 Weeks and Baseline — 0.04 Percent — p=0.999

Primary: Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score — -14.97; -7.21 units on scale